Cancer

Inclusion Criteria

- Patient has provided written informed consent.
  - Patient meets one of the following criteria:
   -- Already enrolled and on treatment with copanlisib in Bayer-sponsored Study 17067 (CHRONOS-3), OR
   -- Already enrolled and on treatment with copanlisib in an investigator-initiated research (IIR)/institution-sponsored collaborative study (ISCS), OR
   -- Currently on copanlisib treatment prescribed by a healthcare provider.
  - Patient is deriving an objective favorable response from copanlisib in the opinion of their healthcare provider.
  - Patient has no suitable alternative treatments available.
  - Women of childbearing potential and men must agree to use effective contraception when sexually active due to potential embryo-fetal toxicity for 1 month after the last dose.

Exclusion Criteria

- Patients who may have developed a disease/condition/toxicity that would conflict with continuing to receive copanlisib treatment.
  - Patients on treatment with rituximab (R) either alone or in combination with chemotherapy, including an alkylating agent (e.g. bendamustine [R-B] or cyclophosphamide, hydroxydoxorubicin, vincristine, prednisone [R-CHOP]) for relapsed indolent non-Hodgkin's lymphoma (iNHL).